WP
OBIO icon

Woodline Partners’s Orchestra BioMed OBIO Stock Holding History

Woodline Partners’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-126,061
Closed -$1.26M – 737
2022
Q4 		$1.26M Hold
126,061
– – 0.02% 526
2022
Q3 		$1.25M Sell
126,061
-277,638
-69% -$2.75M 0.02% 516
2022
Q2 		$4.02M Hold
403,699
– – 0.06% 289
2022
Q1 		$4M Hold
403,699
– – 0.06% 265
2021
Q4 		$4.07M Hold
403,699
– – 0.06% 312
2021
Q3 		$3.99M Hold
403,699
– – 0.07% 288
2021
Q2 		$4.12M Hold
403,699
– – 0.08% 241
2021
Q1 		$4.52M Hold
403,699
– – 0.1% 203
2020
Q4 		$5.17M Buy
403,699
+3,699
+0.9% +$42.2K 0.14% 157
2020
Q3 		$4.4M Buy
+400,000
New +$4.49M 0.14% 139

Other funds holding OBIO

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
SFG
SVB Financial Group Dallas, Texas $434K AUM 277.67% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Woodline Partners's OBIO Position: Q1 2023 in Review

Woodline Partners sold out of Orchestra BioMed (OBIO) in Q1 2023, closing a stake of 126,061 shares — an estimated $1.26M sold.

Woodline Partners first reported a position in OBIO in Q3 2020 and held it in 10 quarters. The position peaked at $5.17M in Q4 2020. 22 funds tracked by Wall St. Rank hold OBIO as of Q1 2023.

  • Woodline Partners reported no remaining Orchestra BioMed position as of Q1 2023 after selling out during the quarter.
  • Woodline Partners sold 126,061 Orchestra BioMed shares in Q1 2023, an estimated $1.26M.
  • Woodline Partners first reported a position in Orchestra BioMed in Q3 2020 and held it in 10 quarters.
  • Woodline Partners's Orchestra BioMed position peaked at $5.17M in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2023.

Based on Woodline Partners's 13F filing for Q1 2023, filed 15 May 2023.